What is HIV and hepatitis C co-infection?

Last reviewed: September 21, 2026

HIV/HCV coinfection means living with HIV and hepatitis C. Both can spread through blood, and untreated HCV can damage the liver faster in people with HIV. Hepatitis C is usually curable with direct-acting antiviral pills, often over 8–12 weeks, while HIV treatment continues. An HCV RNA test identifies current infection; a positive antibody test alone may reflect a past infection.^{[1][2][3][6][14]}

How common coinfection is, and why the two viruses travel together

The often-quoted 21% figure comes from 2009 data: that proportion of tested adults with HIV had evidence of past or present HCV infection. NIH and historical HRSA materials repeat approximately one in five. This is not a measured 2026 prevalence of active hepatitis C, and a past positive antibody result is not the same as current RNA-positive infection. Estimates from different years and populations should not be treated as interchangeable.^[2][1][4]

HCV exposure has been especially common among people with HIV who have shared injection equipment. CDC cites estimates of 62%–80%, and HIV.gov cites nearly 75% among people reporting a history of injection drug use. These are historical estimates from different populations, not a current infection rate for every person who injects drugs. Access to sterile equipment, testing and treatment helps reduce risk.^[1][3]

“Because both HIV and HCV can spread via blood, a major risk factor for both HIV and HCV infection is injection drug use,” and “in the United States, HCV is spread mainly by sharing needles or other injection drug equipment”^[2]. Everything that carries blood — syringes, cookers, cotton, water — can carry both.

Sexual transmission of hepatitis C is less common but real. CDC notes that “sexual transmission can happen among MSM with HIV, especially among those who have unprotected anal intercourse, use sex toys, or use non-injection drugs”^[1]. HIV.gov adds that HCV sexual transmission “is most likely to happen during anal intercourse among men who have sex with men, particularly for the receptive partner,” and that coinfection also increases the chance of passing hepatitis C perinatally^[3].

Why coinfection accelerates liver disease

Untreated chronic HCV can lead to fibrosis, cirrhosis, liver failure and liver cancer over time. The pace varies with factors such as age, alcohol use, immune health and treatment. A historical average time to cirrhosis cannot predict an individual’s course.^[5]

NIH summarizes older studies in which HIV/HCV coinfection was associated with greater liver-disease progression, including a meta-analysis reporting roughly threefold higher risk of cirrhosis or decompensated liver disease. Those data do not describe the prognosis of someone whose HCV has now been cured with modern therapy. HIV treatment and timely HCV cure are central to reducing risk, especially when CD4 counts are low.^[5][1][3]

The takeaway is not fear — it is timing. Faster progression is exactly why testing and curing hepatitis C early is worth pushing for.

Getting tested: two steps, and who needs it

Everyone with HIV should be tested for HCV. Repeat testing is recommended with ongoing exposure risks and during each pregnancy. CDC distinguishes an initial test because someone has HIV from periodic testing driven by ongoing exposures; HIV status alone does not define a universal annual testing schedule.^{[14][2][3][1]}

Testing usually begins with HCV antibodies, with automatic HCV RNA testing when antibodies are reactive. Detectable RNA indicates current infection; antibodies alone may reflect infection that cleared or was cured. With recent exposure or impaired antibody responses, a clinician may order RNA even if the antibody test is negative. After cure, use RNA to check for reinfection because antibodies often remain positive.^[14][13][2]

Hepatitis C is curable — including for people with HIV

Access policy update, September 2026: H.R.9682 proposes a national hepatitis C elimination program, including expanded access to testing and treatment. The introduced bill is not an operating assistance fund and does not create an enrollment option today.^[16] Read about the House and Senate proposals and advocacy →

People with HIV can receive curative HCV treatment, with outcomes comparable to people without HIV when drug interactions and other clinical needs are addressed. Modern regimens cure more than 95% of many treated populations, commonly after 8–12 weeks of pills, but the regimen and duration depend on cirrhosis, prior treatment and other factors. Cure is generally confirmed by undetectable HCV RNA at least 12 weeks after treatment ends—SVR12—not simply by finishing the pills.^{[13][5][6][3][2]}

Two examples illustrate the evidence; they are not head-to-head comparisons or the only treatment options:

• Glecaprevir/pibrentasvir — the open-label EXPEDITION-2 study enrolled 153 adults with HIV/HCV: 137 without cirrhosis received eight weeks and 16 with compensated cirrhosis received 12 weeks. SVR12 was 150/153 (98%) overall. The reported 136/136 and 14/15 subgroup results exclude two nonvirologic outcomes and should not be mistaken for the enrolled denominators.^[11][7]
• Sofosbuvir/velpatasvir — 12 weeks in 106 adults with coinfection on stable ART produced an SVR12 of 95%. In the MINMON study, SVR12 was 94.6% among participants with HIV versus 95.3% among those without^[6].

Other regimens also have evidence in HIV/HCV coinfection, including elbasvir/grazoprevir, ledipasvir/sofosbuvir and salvage regimens after prior treatment failure. Duration is regimen-specific. The guidance’s caution against an eight-week ledipasvir/sofosbuvir course in people with HIV does not prohibit all eight-week HCV treatment. Current simplified guidance allows eight weeks of glecaprevir/pibrentasvir with food for eligible treatment-naive adults with compensated cirrhosis, after checking all eligibility criteria and interactions.^[12][7]

Drug interactions and other treatment checks

The main clinical task is making sure the hepatitis C pills and the HIV pills get along. HHS guidelines state that “several ARV drugs and HCV DAAs have the potential for clinically significant pharmacokinetic drug–drug interactions when used in combination,” and that “before starting HCV therapy, the ART regimen may need to be modified to reduce the drug–drug interaction potential” — with specific pairings listed in the guidelines' Table 18^[5]. AASLD/IDSA echo that treatment “requires continued awareness and attention to the complex drug-drug interactions that can occur between DAAs and antiretroviral medications”^[7]. NIH's plain-language version: “some HIV and HCV medicines cannot be safely used together because of drug-drug interactions”^[2].

Bring a complete medication and supplement list to the HCV treatment visit. Your clinician should check current interaction guidance and product labels, assess liver disease, and screen for hepatitis B because HCV treatment can reactivate HBV. If ART needs changing, the switch and any later return must be planned together; do not stop HIV treatment to take HCV medicine. The timing of a safe switch may extend beyond the HCV pill course.^[6][3]

Ask your HIV clinic or case manager about insurance and medication assistance. HRSA’s cited page describes historical ADAP access; current formularies and eligibility must be checked. Florida’s July 2026 ADAP formulary lists several HCV antivirals.^[15] Cure removes the current HCV infection, but reinfection remains possible. People with cirrhosis need continued liver-cancer surveillance even after cure.^[13][4]

Related questions

Related from RiseUpToHIV